

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
14 September 2023 (14.09.2023)



(10) International Publication Number  
**WO 2023/168520 A1**

(51) International Patent Classification:

*C07K 16/12* (2006.01) *C07K 14/21* (2006.01)  
*A61K 39/104* (2006.01) *C07K 14/34* (2006.01)  
*A61K 39/385* (2006.01) *C07K 14/195* (2006.01)  
*A61P 31/04* (2006.01) *C07K 14/245* (2006.01)  
*A61P 37/04* (2006.01) *G01N 33/569* (2006.01)  
*C07H 15/04* (2006.01)

(21) International Application Number:

PCT/CA2023/050297

(22) International Filing Date:

07 March 2023 (07.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/317,245 07 March 2022 (07.03.2022) US

(71) Applicant: **NATIONAL RESEARCH COUNCIL OF CANADA** [CA/CA]; 1200 Montreal Road, Ottawa, Ontario K1A0R6 (CA).

(72) Inventors: **COX, Andrew David**; 2160 Dutton Crescent, Ottawa, Ontario K1J 6K4 (CA). **VINOGRADOV, Evguenii**; 461 Wentworth Avenue, Ottawa, Ontario K2B

5J9 (CA). **SAUVAGEAU, Janelle**; 110 Rideau Terrace, Unit 7, Ottawa, Ontario K1M 0Z2 (CA).

(74) Agent: **VICKERS, Mark F.** et al.; Borden Ladner Gervais LLP, 100 Queen Street, Suite 1300, Ottawa, Ontario K1P 1J9 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: PREVENTING/TREATING PSEUDOMONAS AERUGINOSA INFECTION

2- $\alpha$ -Rha-3- $\alpha$ -Rha-3- $\alpha$ -Rha- A-PS repeating unit  
A B C

$\alpha$ -Rha3OMe-4-( $\alpha$ -Rha3OMe-4-)<sub>4</sub>-4- $\alpha$ -Man3OMe-2-tetritol-1*d* OS1  
E F L X

Double oxidized A-PS for conjugation:

$\alpha$ -Rha3OMe-4-( $\alpha$ -Rha3OMe-4-)<sub>4</sub>-4- $\alpha$ -Man3OMe-2-Glyceraldehyde-3*d* OS2  
E F L X

$\alpha$ -Rha3OMe-4-( $\alpha$ -Rha3OMe-4-)<sub>4</sub>-4- $\alpha$ -Man3OMe-4- $\alpha$ -Man-4- $\alpha$ -Man-4- $\alpha$ -Rha2OMe A-PS1  
E F L M K D H

$\alpha$ -Rha3OMe-4-( $\alpha$ -Rha3OMe-4-)<sub>4</sub>-4- $\alpha$ -Man3OMe-4- $\alpha$ -Man-4- $\alpha$ -Man-4- $\alpha$ -Man2OMe A-PS2  
E F L M K D' G

FIG. 1

(57) Abstract: The present disclosure relates generally to compounds, compositions, antibodies, and methods for raising and utilising an immune response in a subject, comprising administering to a subject an isolated or synthesised *Pseudomonas aeruginosa* glycan, optionally linked to a carrier protein in the form of a glycoconjugate. Further provided is an antibody that selectively binds a *Pseudomonas aeruginosa* glycan or glycoconjugate as described in this disclosure.

[Continued on next page]

WO 2023/168520 A1

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*